Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Production of Antibiotics01:27

Production of Antibiotics

Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor cell-derived extracellular vesicles foster the immunosuppressive landscape of pancreatic cancer.

The Journal of clinical investigation·2026
Same author

The Bacillus subtilis circadian clock coordinates intricate spatiotemporal organisation.

Nature communications·2026
Same author

Organelle interplay in host responses and mycobacterial resilience.

EMBO reports·2026
Same author

Development of Isoniazid-Pyrazole Hybrids as Potential Antitubercular Agents.

International journal of molecular sciences·2026
Same author

Multiple defects in macrophage antibacterial responses support intracellular survival of <i><i>Mycobacterium</i> abscessus</i> in cystic fibrosis.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Intranasal lipid nanocapsule administration of the new lipophenol quercetin-3-O-DHA-7-O-iPr reduces carbonyl stress and improves behavior in a mouse model of Alzheimer's disease.

Drug delivery and translational research·2026

Related Experiment Video

Updated: Jun 13, 2026

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray
07:35

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray

Published on: April 25, 2014

12.7K

Mapping of Mycobacterial Enzymes Involved in Triacylglycerol Accumulation as Intrabacterial Lipid Inclusions Using

Romain Avellan1, Jordan Lehoux2, Thomas Francis1

  • 1Aix-Marseille Univ., CNRS, LISM UMR7255, IMM FR3479, 31 Chemin Joseph Aiguier, 13009 Marseille, France.

ACS Infectious Diseases
|May 29, 2025
PubMed
Summary

Researchers identified key enzymes involved in forming lipid inclusions in Mycobacterium abscessus. FadD15 was validated as a pivotal enzyme crucial for intrabacterial lipid inclusion formation and long-term bacterial survival.

Keywords:
Mycobacterium abscessusactivity-based protein profilingcyclipostins and cyclophostinlipid metabolismmultitarget inhibitor-like activity-based probesoxadiazolone

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.6K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

1.6K

Related Experiment Videos

Last Updated: Jun 13, 2026

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray
07:35

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray

Published on: April 25, 2014

12.7K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.6K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

1.6K

Area of Science:

  • Microbiology
  • Biochemistry
  • Molecular Biology

Background:

  • Lipids are crucial for mycobacteria, impacting host interactions, cell wall maintenance, growth, and persistence.
  • Intrabacterial lipid inclusions (ILI), primarily triacylglycerol, are vital for mycobacterial long-term survival within hosts.
  • Enzymes governing ILI formation and degradation in mycobacteria are largely unknown.

Purpose of the Study:

  • To identify enzymes involved in the anabolism of intrabacterial lipid inclusions (ILI) in *Mycobacterium abscessus*.
  • To investigate the role of specific enzymes in triacylglycerol storage and ILI formation.

Main Methods:

  • Utilized bio-orthogonal click-chemistry activity-based protein profiling (CC-ABPP) with novel oxadiazolone (OX) and cyclophostin (CyC) probes.
  • Applied CC-ABPP to *Mycobacterium abscessus* cultures under conditions promoting triacylglycerol and ILI production (carbon excess, nitrogen deprivation).
  • Validated identified enzymes through colocalization studies and functional assays.

Main Results:

  • Identified a set of 65 enzymes potentially involved in ILI anabolism.
  • Validated MAB_1978c/FadD15, a long-chain-fatty-acid--CoA ligase, as a pivotal enzyme in ILI formation.
  • Demonstrated that FadD15 colocalizes on ILI and significantly contributes to their formation in *M. abscessus*.

Conclusions:

  • The study elucidates key enzymatic players in mycobacterial lipid metabolism and ILI biogenesis.
  • FadD15 is identified as a critical enzyme for ILI formation, highlighting its importance in *Mycobacterium abscessus* physiology.
  • Findings provide insights into mycobacterial persistence mechanisms and potential therapeutic targets.